Table 4.
Odds ratios for HPV persistence by proportion of CD8+ lymphocyte immunophenotypic subsets
| Marker | Median quartile values* | HPV negative group‡ | Persistent HPV positive group‡ | Long term persistent HPV positive group‡ | ||||
|---|---|---|---|---|---|---|---|---|
| N | N | OR† | 95% CI | N | OR† | 95% CI | ||
| CD69+CD8+ | ||||||||
| 1st quartile | 0.10% | 78 | 16 | 1 | 4 | 1 | ||
| 2nd quartile | 0.23% | 60 | 24 | 1.7 | 0.84–3.6 | 5 | 0.97 | 0.23–4.0 |
| 3rd quartile | 0.46% | 66 | 20 | 1.4 | 0.66–2.9 | 9 | 2.1 | 0.59–7.5 |
| 4th quartile | 1.2% | 50 | 20 | 1.8 | 0.86–3.9 | 9 | 2.7 | 0.76–10.0 |
| p-trend | =0.195 | =0.053 | ||||||
|
| ||||||||
| HLADR+CD3+CD8+ | ||||||||
| 1st quartile | 20.6% | 68 | 20 | 1 | 5 | 1 | ||
| 2nd quartile | 34.1% | 64 | 12 | 0.60 | 0.27–1.3 | 1 | 0.17 | 0.02–1.6 |
| 3rd quartile | 44.2% | 56 | 23 | 1.2 | 0.57–2.4 | 10 | 1.5 | 0.46–5.0 |
| 4th quartile | 57.3% | 62 | 26 | 1.10 | 0.54–2.2 | 12 | 1.4 | 0.44–4.6 |
| p-trend | =0.482 | =0.190 | ||||||
|
| ||||||||
| CD45RO+CD27+CD8+ | ||||||||
| 1st quartile | 21.3% | 62 | 25 | 1 | 8 | 1 | ||
| 2nd quartile | 30.0% | 65 | 21 | 0.77 | 0.39–1.5 | 10 | 1.1 | 0.37–3.0 |
| 3rd quartile | 37.3% | 65 | 16 | 0.67 | 0.32–1.4 | 5 | 0.79 | 0.23–2.7 |
| 4th quartile | 45.4% | 60 | 19 | 0.81 | 0.40–1.6 | 5 | 0.80 | 0.24–2.7 |
| p-trend | =0.485 | =0.619 | ||||||
|
| ||||||||
| CD45RO+CD27−CD8+ | ||||||||
| 1st quartile | 11.5% | 68 | 14 | 1 | 1 | 1 | ||
| 2nd quartile | 20.9% | 68 | 16 | 1.1 | 0.49 – 2.4 | 8 | 7.5 | 0.90 – 63.3 |
| 3rd quartile | 27.7% | 57 | 21 | 1.9 | 0.87 – 4.1 | 9 | 11.5 | 1.4 – 96.2 |
| 4th quartile | 41.5% | 59 | 30 | 2.3 | 1.1 – 4.7 | 10 | 8.8 | 1.1 – 72.3 |
| p-trend | =0.010 | =0.041 | ||||||
*
For HPV Negative and HPV positive groups
‡
HPV group as defined in the methods section
†
Odds ratios for the HPV positive and long term HPV positive groups compared to the HPV negative group, adjusted for age.